Frankfurt
06.12.24 | 08:01
0,000 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CYXONE Aktie jetzt für 0€ handeln | |||||
| 27.12.24 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 27.12.2024 | 1.376 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 27.12.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 27.12.2024ISIN NameCA33812R1091 FISSION... ► Artikel lesen | |
| 16.12.24 | Nasdaq Stockholm AB: Delisting of Cyxone AB from Nasdaq First North Growth Market | 251 | GlobeNewswire | On December 9, 2024, Cyxone AB was declared bankrupt by Malmö District Court.
According to item 8.2.7 of the Nasdaq First North Growth Market Rulebook, the exchange may decide to delist the financial... ► Artikel lesen | |
| 06.12.24 | XFRA 4CX: AUSSETZUNG/SUSPENSION | 278 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCYXONE AB SK-,75... ► Artikel lesen | |
| 12.11.24 | Nasdaq Stockholm AB: Cyxone AB receives observation status | 304 | GlobeNewswire | On November 8, 2024, Cyxone AB (the "Company") disclosed a press release with
information on the Company's financial situation.
The rules of Nasdaq First North Growth Market state that an issuer can... ► Artikel lesen | |
| 08.11.24 | Nasdaq Stockholm AB: Lift of Suspension in Cyxone AB at FNSE | 329 | GlobeNewswire | Lifting of Suspension
At Trading Venue FNSE
Issuer: Cyxone AB, LEI: 54930034OH16ROAY4K87
--------------------------------------------------------------------------------
Instruments:... ► Artikel lesen |
5 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 3,600 | -3,43 % | INSIDERALARM bei Evotec! Valneva mit neuem KURSZIEL! Vidac Pharma Aktie bald mit neuem ALLZEITHOCH? | Endlich! Bei Evotec sorgen Insider für ein wichtiges Signal. Die Aktie reagiert zwar noch nicht, aber mittelfristig könnte sich dies als Kaufsignal herausstellen. Derzeit herrscht noch Skepsis. Bullish... ► Artikel lesen | |
| NOVAVAX | 6,561 | -2,76 % | Novavax Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
| COSCIENS BIOPHARMA | 1,860 | -2,62 % | COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update | COSCIENS Board of Directors approves a plan to voluntarily delist from Nasdaq, while retaining the Company's listing on the TSX TORONTO, ONTARIO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 2,035 | +1,24 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference | Clinical trial advances to anticipated final cohort for INSTASYL siRNA lead product candidate PH-7625th cohort patients now being treated in on-going clinical studyKing of Prussia, Pennsylvania--(Newsfile... ► Artikel lesen | |
| ORAGENICS | 1,160 | +9,95 % | ORAGENICS INC - 8-K, Current Report | ||
| LEXICON PHARMACEUTICALS | 0,890 | -4,76 % | Lexicon Pharmaceuticals, Inc.: Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista in Type 1 Diabetes | Data obtained from ongoing third-party funded, investigator-sponsored trials have been submitted in effort to address the December 2024 complete response letter Company seeks alignment on reasonable... ► Artikel lesen | |
| OUTLOOK THERAPEUTICS | 0,788 | -1,38 % | Outlook Therapeutics, Inc.: Outlook Therapeutics Requests Type A Meeting with FDA | ISELIN, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment... ► Artikel lesen | |
| CSTONE PHARMACEUTICALS | 1,380 | +4,55 % | CStone Pharmaceuticals Announces 2024 Annual Results and Recent Business Progress | Financial Performance: Strong Year-over-Year Improvement- Total Revenue: RMB 407.2 million, including RMB 232.1 million in licensing and royalty income.- ... ► Artikel lesen | |
| GENSCRIPT BIOTECH | 1,858 | 0,00 % | GenScript Biotech Corporation: GenScript Biotech Demonstrates Profitable Scale and Strategic Leadership in H1 2025, Establishing Clear Industry Leadership Through Accelerated Growth and Innovation | Rising Global Footprint, Best-in-Class Innovation, and ESG Excellence Set Stage for Sustained Value Creation
PISCATAWAY, N.J., Aug. 17, 2025 /PRNewswire/ --... ► Artikel lesen | |
| KRYSTAL BIOTECH | 128,60 | +0,19 % | Krystal Biotech präsentiert Wachstumsstrategie und Herausforderungen auf Gesundheitskonferenz | ||
| ALIGOS THERAPEUTICS | 9,100 | -5,21 % | Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting | ||
| Q32 BIO | 1,380 | +0,73 % | Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update | -- Dosing of patients in Part A open-label extension (OLE) and Part B of SIGNAL-AA ongoing; SIGNAL-AA Part B topline data readout on-track for 1H'26 --
-- Strengthened... ► Artikel lesen | |
| LEAP THERAPEUTICS | 0,240 | 0,00 % | Leap Therapeutics, Inc.: Leap Therapeutics Reports Second Quarter 2025 Financial Results | CAMBRIDGE, Mass., Aug. 14, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology... ► Artikel lesen | |
| ACTINOGEN | 0,015 | -3,23 % | Actinogen Medical - XanaMIA study enrols 100th patient | Actinogen Medical announced on 30 June that it has recruited the 100th patient for its ongoing XanaMIA Phase IIb/III study assessing lead candidate Xanamem (emestedastat) in patients with biomarker-positive... ► Artikel lesen | |
| XENETIC BIOSCIENCES | 3,040 | 0,00 % | Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results | Expanded strategic partnership with The Scripps Research Institute to advance proof-of-concept studies and further develop its program combining systemic DNase I with CAR T-cell therapiesEnded the quarter... ► Artikel lesen |
Das Unternehmen CYXONE AB kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,000 Euro.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CYXONE AB finden Sie auf Wallstreet Online.